About Hilleman

Hilleman Laboratories is a global vaccine research & development organization focused on making affordable vaccines using innovation to address gaps that exist in low resource settings. Hilleman Labs acts as a catalyst in bridging the gap between academic research and product development by targeting novel vaccines and increasing the efficiency of existing vaccines.

Know More

Vision

Developing vaccines for global health

Company Presentation

mission

Hilleman Laboratories is committed to developing high impact, affordable vaccines for people in developing countries in an innovative and sustainable manner.

In The News

  • EVI and Hilleman Laboratories announce partnership to assess a new vaccine against Shigella

    October 07th, 2019

    Funding from European and Developing Countries Clinical Trials Partnership (EDCTP) will allow testin

    Know More
  • Hilleman Laboratories licenses Oral Cholera Vaccine HillcholĀ® to Bharat Biotech

    June 26th, 2019

    Collaboration seeks to accelerate the development, licensure, manufacture and supply of an affordabl

    Know More
  • Hilleman Laboratories announces creation of new Strategic Advisory Committe

    January 18th, 2019

    Hilleman Laboratories announces creation of new Strategic Advisory Committe

    Know More
  • Cheap, painless vaccine patches to be available in India in a couple of years

    December 11th, 2018

    Cheap, painless vaccine patches to be available in India in a couple of years

    Know More
  • Hilleman Labs announces publication of original research on Heat Stable Rotavirus Vaccines

    September 11th, 2018

    Hilleman Laboratories today announced the publication of original research as well as expert comment

    Know More

Science & Innovation

Our Approach

We have established modern research and development laboratories to play a crucial role in the process of health development in India and other under-developed countries.

Vaccine Innovation

We are collaborating with the global public health community on the development of optimized vaccines with target product profiles relevant to low income countries.

Current R&D

The World Health Organization estimates that 600,000 children under the age of 5 die annually due to rotavirus diarrhoea and another two million are hospitalized.